Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Learn more about the possibilities of this page

Oramed Pharmaceuticals Stock

Price
Target price
€2.32

€2.32

7.160%
0.157
7.160%
-
 
06.05.24 / Tradegate WKN: A1CTNU / Symbol: ORMP / Name: Oramed / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Oramed Pharmaceuticals in the next few years
Wizard

Description Oramed

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company based in Israel. It is focused on the development of oral drug delivery systems. The company's lead drug candidate, ORMD-0801, is an oral insulin capsule used for the treatment of diabetes.

Oramed has completed multiple clinical trials for ORMD-0801, demonstrating its safety and efficacy in reducing blood glucose levels among patients with type 2 diabetes. The company has also recently announced the initiation of clinical trials for ORMD-0901, an oral GLP-1 analog capsule used for the treatment of type 2 diabetes and obesity.

Oramed was founded in 2002 and went public in 2007. Its shares are traded on the Nasdaq Global Market under the symbol ORMP. As of August 2021, the company had a market capitalization of approximately $230 million.

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Oramed Pharmaceuticals is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Oramed

sharewise wants to provide you with the best news and tools for Oramed, so we directly link to the best financial data sources.

Financials

News

Broker